Clinical Trial

CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma

Name: CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma — clinical trial record (NCT07249073)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

1. Objective to evaluate the safety and tolerability of CAR19-BCMA dual-target CAR-T in the treatment of relapsed / refractory multiple myeloma. 2. To determine the maximum tolerated dose (MTD) of car19-bcma dual target car-t in the treatment of relapsed / refractory multiple myeloma.

Trial Details

NCT Number	NCT07249073
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China Collaborators: Hebei Taihe Chunyu Biotechnology Co., Ltd
Conditions	Multiple Myeloma
Enrollment	9 participants
Start Date	2025-03-28
Primary Completion	2028-03-27 (estimated)
Study Completion	2029-03-27 (estimated)
Updated on ClinicalTrials.gov	2025-11-25